Listen now (13 min) | New data shows that natalizumab has an impact on chronic active lesions, including slowly expanding lesions, and indicates that natalizumab is a potentially effective treatment for smouldering MS.
0 subscriptions will be displayed on your profile (edit)
Skip for now
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.
Why is natalizumab not licensed to treat…
Listen now (13 min) | New data shows that natalizumab has an impact on chronic active lesions, including slowly expanding lesions, and indicates that natalizumab is a potentially effective treatment for smouldering MS.
Create your profile
Only paid subscribers can comment on this post
Check your email
For your security, we need to re-authenticate you.
Click the link we sent to , or click here to sign in.